英国儿童淋巴瘤研究组X方案——III期纵隔非霍奇金淋巴瘤的有效治疗方法。
UKALL X--an effective treatment for stage III mediastinal non-Hodgkin's lymphoma.
作者信息
Wheeler K, Chessells J M
机构信息
Department of Haematology and Oncology, Hospital for Sick Children, London.
出版信息
Arch Dis Child. 1990 Mar;65(3):252-4. doi: 10.1136/adc.65.3.252.
Fifteen children with mediastinal non-Hodgkin's lymphoma were treated with MRC UKALL X, the current national protocol for acute lymphoblastic leukaemia. The treatment was well tolerated, and in a minimum follow up period of 46 months the event free survival of 93% was significantly better than that in a group of historical controls treated with intermittent chemotherapy regimens whose survival was only 57%. We conclude that intensive induction and consolidation treatment, with continued oral drugs, provides an effective approach to the management of mediastinal non-Hodgkin's lymphoma.
15名纵隔非霍奇金淋巴瘤患儿接受了英国医学研究委员会（MRC）UKALL X方案的治疗，该方案是目前用于急性淋巴细胞白血病的全国性方案。治疗耐受性良好，在至少46个月的随访期内，无事件生存率为93%，显著优于一组接受间歇化疗方案治疗的历史对照患者，其生存率仅为57%。我们得出结论，强化诱导和巩固治疗，辅以持续口服药物，为纵隔非霍奇金淋巴瘤的治疗提供了一种有效方法。
Zotero 插件